Literature DB >> 22504462

Morphine at "sub-analgesic" background infusion rate plus low-dose PCA bolus control pain better and is as safe as twice a bolus-only PCA regimen: a randomized, double blind study.

Ian White1, Ronen Ghinea, Shmuel Avital, Shoshana Chazan, Oleg Dolkart, Avi A Weinbroum.   

Abstract

Morphine for postoperative pain control is commonly titrated via intravenous patient-controlled analgesia (IV-PCA). An IV morphine background infusion is rarely used. We investigated whether analgesia is effectively attained and morphine consumption is reduced if PCA titration is coadjuvated by a continuous infusion protocol. Following colorectal cancer surgery, consenting patients were randomized to receive a minimal ("sub-analgesic") dose of morphine 0.01 mg/kg/h background infusion plus a 0.01 mg/kg bolus (BI), or a 1.5mg bolus-only morphine (B0) (bolus ratio ∼1:2). Bolus lockout time was 7 min in either case. All patients received 0.1mg/kg morphine before protocol initiation, and diclofenac 75 mg intramuscularly b.i.d. during the study period, lasting 48 h. Eighty-six patients (51 males, age 26-95 years) participated in the study. The total mean morphine consumption during the 48 h was 25% lower in the BI than in the B0 group (P<0.05). Although the former applied the PCA device for boluses 19% less than the latter (P<0.05), their pain score was lower (P<0.05) most of the time, and they reported greater satisfaction (P<0.05) on a 10-scale numerical rating score. Pre- and postoperative vital signs were similar for both groups. No patient depicted hypoxemia or lapsed into deep sedation. Four BI and three B0 patients required treatment for postoperative nausea and vomiting. One BI patient had transient pruritus and one B0 69-year individual became disoriented 24h into treatment; either event subsided soon after stopping their respective regimen without the need for treatment. The main conclusions of the results are that very-low-dose background morphine infusion combined with small-dose PCA boluses may provide better pain relief, lower morphine consumption, and minimal complication rate as a 1.5mg PCA bolus-only protocol.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22504462     DOI: 10.1016/j.phrs.2012.03.016

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

1.  [Anesthesiological acute pain therapy in Germany: telephone-based survey].

Authors:  C L Lassen; F Link; N Lindenberg; T W Klier; B M Graf; C Maier; C H R Wiese
Journal:  Anaesthesist       Date:  2013-05-15       Impact factor: 1.041

2.  Finding the 'ideal' regimen for fentanyl-based intravenous patient-controlled analgesia: how to give and what to mix?

Authors:  Seokyung Shin; Keoung Tae Min; Yang Sik Shin; Hyung Min Joo; Young Chul Yoo
Journal:  Yonsei Med J       Date:  2014-04-01       Impact factor: 2.759

3.  [Pediatric perioperative systemic pain therapy: Austrian interdisciplinary recommendations on pediatric perioperative pain management].

Authors:  B Messerer; G Grögl; W Stromer; W Jaksch
Journal:  Schmerz       Date:  2014-02       Impact factor: 1.107

4.  A comparison of 2 intravenous patient-controlled analgesia modes after spinal fusion surgery: Constant-rate background infusion versus variable-rate feedback infusion, a randomized controlled trial.

Authors:  Seung Hyuk Lee; Chong Wha Baek; Hyun Kang; Yong-Hee Park; Geun Joo Choi; Yong Hun Jung; Young Cheol Woo
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

5.  Effect of preoperative flupirtine on postoperative morphine sparing in patients undergoing total abdominal hysterectomy.

Authors:  D Thapa; V Ahuja; C Dass; S Gombar; A Huria
Journal:  Saudi J Anaesth       Date:  2016 Jan-Mar

6.  Postoperative Pain and Intravenous Patient-Controlled Analgesia-Related Adverse Effects in Young and Elderly Patients: A Retrospective Analysis of 10,575 Patients.

Authors:  Jae Chul Koh; Jinae Lee; So Yeon Kim; Sumin Choi; Dong Woo Han
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.